Fully automated radiosynthesis of [68Ga]Ga-FAPI-46 with cyclotron produced gallium

IF 4.4 Q1 CHEMISTRY, INORGANIC & NUCLEAR EJNMMI Radiopharmacy and Chemistry Pub Date : 2023-10-16 DOI:10.1186/s41181-023-00216-0
Adam J. Rosenberg, Yiu-Yin Cheung, Fei Liu, Carina Sollert, Todd E. Peterson, Jonathan A. Kropski
{"title":"Fully automated radiosynthesis of [68Ga]Ga-FAPI-46 with cyclotron produced gallium","authors":"Adam J. Rosenberg,&nbsp;Yiu-Yin Cheung,&nbsp;Fei Liu,&nbsp;Carina Sollert,&nbsp;Todd E. Peterson,&nbsp;Jonathan A. Kropski","doi":"10.1186/s41181-023-00216-0","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Radiopharmaceuticals capable of targeting the fibroblast activation protein have become widely utilized in the research realm as well as show great promise to be commercialized; with [<sup>68</sup>Ga]Ga-FAPI-46 being one of the most widely utilized. Until now the synthesis has relied on generator-produced gallium-68. Here we present a developed method to utilize liquid-target cyclotron-produced gallium-68 to prepare [<sup>68</sup>Ga]Ga-FAPI-46.</p><h3>Results</h3><p>A fully-automated manufacturing process for [<sup>68</sup>Ga]Ga-FAPI-46 was developed starting with the <sup>68</sup>Zn[p,n]<sup>68</sup>Ga cyclotron bombardment to provide [<sup>68</sup>Ga]GaCl<sub>3</sub>, automated purification of the [<sup>68</sup>Ga]GaCl<sub>3</sub>, chelation with the precursor, and final formulation/purification. The activity levels produced were sufficient for multiple clinical research doses, and the final product met all release criteria. Furthermore, the process consistently provides &lt; 2% of Ga-66 and Ga-67 at the 4-h expiry, meeting the Ph. Eur. standards.</p><h3>Conclusions</h3><p>The automated radiosynthesis on the GE FASTlab 2 module purifies the cyclotron output into [<sup>68</sup>Ga]GaCl<sub>3</sub>, performs the labeling, formulates the product, and sterilizes the product while transferring to the final vial. Production of &gt; 40 mCi (&gt; 1480 MBq) of [<sup>68</sup>Ga]Ga-FAPI-46 in excellent radiochemical yield was achieved with all batches meeting release criteria.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579206/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Radiopharmacy and Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s41181-023-00216-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Radiopharmaceuticals capable of targeting the fibroblast activation protein have become widely utilized in the research realm as well as show great promise to be commercialized; with [68Ga]Ga-FAPI-46 being one of the most widely utilized. Until now the synthesis has relied on generator-produced gallium-68. Here we present a developed method to utilize liquid-target cyclotron-produced gallium-68 to prepare [68Ga]Ga-FAPI-46.

Results

A fully-automated manufacturing process for [68Ga]Ga-FAPI-46 was developed starting with the 68Zn[p,n]68Ga cyclotron bombardment to provide [68Ga]GaCl3, automated purification of the [68Ga]GaCl3, chelation with the precursor, and final formulation/purification. The activity levels produced were sufficient for multiple clinical research doses, and the final product met all release criteria. Furthermore, the process consistently provides < 2% of Ga-66 and Ga-67 at the 4-h expiry, meeting the Ph. Eur. standards.

Conclusions

The automated radiosynthesis on the GE FASTlab 2 module purifies the cyclotron output into [68Ga]GaCl3, performs the labeling, formulates the product, and sterilizes the product while transferring to the final vial. Production of > 40 mCi (> 1480 MBq) of [68Ga]Ga-FAPI-46 in excellent radiochemical yield was achieved with all batches meeting release criteria.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用回旋加速器产生的镓进行[68Ga]Ga-FAPI-46的全自动放射合成。
背景:靶向成纤维细胞活化蛋白的放射性药物已在研究领域得到广泛应用,并显示出商业化的巨大前景;[68Ga]Ga-FAPI-46是应用最广泛的材料之一。到目前为止,合成一直依赖于发电机生产的镓-68。在这里,我们提出了一种利用液体靶回旋加速器产生的镓-68制备[68Ga]Ga-FAPI-46的开发方法。产生的活性水平足以用于多种临床研究剂量,最终产品符合所有释放标准。此外,该过程始终提供标准:结论:GE FASTlab 2模块上的自动化放射合成将回旋加速器输出净化为[68Ga]GaCl3,进行标记,配制产品,并在转移到最终小瓶时对产品进行消毒。生产> 40 mCi(> 1480MBq)的[68Ga]Ga-FAPI-46,所有批次都符合释放标准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.20
自引率
8.70%
发文量
30
审稿时长
5 weeks
期刊最新文献
The development of 177Lu-DOTA-CC-PSMA following a unified "Click Chemistry" protocol of synthesizing metal nuclide-conjugated radiopharmaceuticals. In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions. Generic semi-automated radiofluorination strategy for single domain antibodies: [18F]FB-labelled single domain antibodies for PET imaging of fibroblast activation protein-α or folate receptor-α overexpression in cancer. Process validation and preclinical development of a new PET cerebral blood flow tracer [11C]MMP for initial clinical trials. Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1